Abstract
The adhesive interaction of tumor cells with various components of the extracellular matrix (ECM), such as laminin and fibronectin appears to play a crucial role in tumor metastasis. It has been reported that adhesive peptides, such as Tyr-Ile-Gly-Ser-Arg (YIGSR) in laminin and Arg-Gly-Asp (RGD), inhibited adhesion and invasion of various tumor cells to ECM in vitro, and exhibited inhibitory effects on pulmonary metastasis of B16-BL6 melanoma cells in mice. However, large doses of these peptides were required for significant anti-metastatic effects in vivo, probably due to their rapid degradation by various peptidases and their rapid excretion from the blood into the urine. To overcome these problems, the development of an appropriate drug delivery system (DDS) is required to improve in vivo stability and prolong plasma half-lives. Several strategies such as peptide-cyclization and D-amino acid substation have been reported to improve stability in blood by inhibiting enzymatic degradation. However, e ven these approaches have proven insufficient to overcome rapid renal clearance from the circulation. On the other hand, bioconjugation with water-soluble polymeric modifiers could markedly prolong the plasma half-lives by not only increasing peptidase resistance but also impeding renal excretion. In addition, it is possible to strictly control the in vivo pharmacokinetics of a peptide by introducing functional molecules with targeting or slow release capacities to the polymeric modifier. In this review we demonstrate with reference to our recent studies that bioconjugation of adhesive peptides with the appropriate polymeric modifier can enhance antimetastatic activity and may facilitate therapeutic use.
Keywords: Polymeric modifier, Pulmonary metastasis, pegylation, Bioactive proteins, bioconjugation, proteins
Current Drug Targets
Title: Molecular Design of Bioconjugated Cell Adhesion Peptide with a Water-Soluble Polymeric Modifier for Enhancement of Antimetastatic Effect
Volume: 3 Issue: 2
Author(s): Yoko Yamamoto, Yasuo Tsutsumi and Tadanori Mayumi
Affiliation:
Keywords: Polymeric modifier, Pulmonary metastasis, pegylation, Bioactive proteins, bioconjugation, proteins
Abstract: The adhesive interaction of tumor cells with various components of the extracellular matrix (ECM), such as laminin and fibronectin appears to play a crucial role in tumor metastasis. It has been reported that adhesive peptides, such as Tyr-Ile-Gly-Ser-Arg (YIGSR) in laminin and Arg-Gly-Asp (RGD), inhibited adhesion and invasion of various tumor cells to ECM in vitro, and exhibited inhibitory effects on pulmonary metastasis of B16-BL6 melanoma cells in mice. However, large doses of these peptides were required for significant anti-metastatic effects in vivo, probably due to their rapid degradation by various peptidases and their rapid excretion from the blood into the urine. To overcome these problems, the development of an appropriate drug delivery system (DDS) is required to improve in vivo stability and prolong plasma half-lives. Several strategies such as peptide-cyclization and D-amino acid substation have been reported to improve stability in blood by inhibiting enzymatic degradation. However, e ven these approaches have proven insufficient to overcome rapid renal clearance from the circulation. On the other hand, bioconjugation with water-soluble polymeric modifiers could markedly prolong the plasma half-lives by not only increasing peptidase resistance but also impeding renal excretion. In addition, it is possible to strictly control the in vivo pharmacokinetics of a peptide by introducing functional molecules with targeting or slow release capacities to the polymeric modifier. In this review we demonstrate with reference to our recent studies that bioconjugation of adhesive peptides with the appropriate polymeric modifier can enhance antimetastatic activity and may facilitate therapeutic use.
Export Options
About this article
Cite this article as:
Yamamoto Yoko, Tsutsumi Yasuo and Mayumi Tadanori, Molecular Design of Bioconjugated Cell Adhesion Peptide with a Water-Soluble Polymeric Modifier for Enhancement of Antimetastatic Effect, Current Drug Targets 2002; 3 (2) . https://dx.doi.org/10.2174/1389450024605427
DOI https://dx.doi.org/10.2174/1389450024605427 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets Anti-Angiogenic Peptides for Cancer Therapeutics
Current Pharmaceutical Biotechnology Mitochondrial Superoxide Dismutase: A Promising Target for New Anticancer Therapies
Current Medicinal Chemistry A Comparison of Liver MRI and Contrast-Enhanced CT as Standard Workup Before Treatment for Rectal Cancer in Usual Care - A Retrospective Study
Current Medical Imaging Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer
Current Genomics Discussion on the Structural Modification and Anti-tumor Activity of Flavonoids
Current Topics in Medicinal Chemistry Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging
Current Medicinal Chemistry Targeting CREB for Cancer Therapy: Friend or Foe
Current Cancer Drug Targets The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases
Current Cancer Drug Targets How Does Indoleamine 2,3-Dioxygenase Contribute to HIV-Mediated Immune Dysregulation
Current Drug Metabolism Estrone (E1) Based Esters as Potential Inhibitors of Type 3 17β- hydroxysteroid Dehydrogenase (17β-HSD3) in the Treatment of Hormone-Dependent Prostate Cancer
Letters in Drug Design & Discovery Prospective Plant Based Anticancer Lead Molecules
Current Topics in Medicinal Chemistry Schiff Bases and Complexes: A Review on Anti-Cancer Activity
Anti-Cancer Agents in Medicinal Chemistry Therapeutic and Diagnostic Agents based on Bioactive Endogenous and Exogenous Coordination Compounds
Current Medicinal Chemistry Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases
Mini-Reviews in Medicinal Chemistry Targeted Therapies in Bone Sarcomas
Current Cancer Drug Targets Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) Curcumin: A Natural Product for Diabetes and its Complications
Current Topics in Medicinal Chemistry Silencing GPX3 Expression Promotes Tumor Metastasis in Human Thyroid Cancer
Current Protein & Peptide Science Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy
Current Medicinal Chemistry